1. Home
  2. ACAD vs LBTYB Comparison

ACAD vs LBTYB Comparison

Compare ACAD & LBTYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACAD
  • LBTYB
  • Stock Information
  • Founded
  • ACAD 1993
  • LBTYB 2004
  • Country
  • ACAD United States
  • LBTYB Bermuda
  • Employees
  • ACAD N/A
  • LBTYB N/A
  • Industry
  • ACAD Biotechnology: Pharmaceutical Preparations
  • LBTYB Cable & Other Pay Television Services
  • Sector
  • ACAD Health Care
  • LBTYB Telecommunications
  • Exchange
  • ACAD Nasdaq
  • LBTYB Nasdaq
  • Market Cap
  • ACAD 3.4B
  • LBTYB 4.0B
  • IPO Year
  • ACAD 2004
  • LBTYB N/A
  • Fundamental
  • Price
  • ACAD $19.95
  • LBTYB $11.11
  • Analyst Decision
  • ACAD Buy
  • LBTYB
  • Analyst Count
  • ACAD 19
  • LBTYB 0
  • Target Price
  • ACAD $25.33
  • LBTYB N/A
  • AVG Volume (30 Days)
  • ACAD 1.6M
  • LBTYB 195.0
  • Earning Date
  • ACAD 02-26-2025
  • LBTYB 01-01-0001
  • Dividend Yield
  • ACAD N/A
  • LBTYB N/A
  • EPS Growth
  • ACAD N/A
  • LBTYB N/A
  • EPS
  • ACAD 0.78
  • LBTYB 4.23
  • Revenue
  • ACAD $929,236,000.00
  • LBTYB $4,341,900,000.00
  • Revenue This Year
  • ACAD $36.88
  • LBTYB $2.22
  • Revenue Next Year
  • ACAD $8.01
  • LBTYB N/A
  • P/E Ratio
  • ACAD $25.70
  • LBTYB $2.54
  • Revenue Growth
  • ACAD 47.06
  • LBTYB 3.53
  • 52 Week Low
  • ACAD $14.15
  • LBTYB $11.02
  • 52 Week High
  • ACAD $26.56
  • LBTYB $21.90
  • Technical
  • Relative Strength Index (RSI)
  • ACAD 60.25
  • LBTYB 26.20
  • Support Level
  • ACAD $19.52
  • LBTYB $11.80
  • Resistance Level
  • ACAD $20.29
  • LBTYB $11.40
  • Average True Range (ATR)
  • ACAD 0.68
  • LBTYB 0.02
  • MACD
  • ACAD 0.08
  • LBTYB 0.03
  • Stochastic Oscillator
  • ACAD 72.62
  • LBTYB 12.33

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

About LBTYB Liberty Global Ltd. Class B

Liberty Global is a holding company with interests in several telecom companies in the UK, Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty is the owner of the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile-network-operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

Share on Social Networks: